MosaiQ™ COVID-19 Antibody Microarray
Quotient response to COVID-19
MosaiQ COVID-19 Antibody Microarray
Learn more

Latest updates

Quotient laboratory
News
Quotient Limited to Publish Quarterly Investor Presentation

JERSEY, Channel Islands, August 4, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today published the latest investor presentation associated with the earnings call for fiscal quarter ended June 30, 2020.

Quotient laboratory
News
Quotient Limited Reports First Quarter Fiscal 2021 Results and Business Update

•    Significant progress in three targeted areas of MosaiQ development – COVID-19 antibody test, potential new applications, and transfusion diagnostics 
•    Ten commercial placements of MosaiQ platform in Europe and the US

Quotient laboratory
News
Quotient Announces Equity Awards

JERSEY, Channel Islands, 23 July 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland today announced that Dr. Isabelle Buckle, Ph.D. and Dr. Catherine Larue, Ph.D.

Quotient laboratory
News
Quotient Announces Appointment of Two New Board Members

JERSEY, Channel Islands, 23 July 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland today announced changes in the composition of its board of directors that will take effect later this year.

Lab
News
Quotient Limited Reports Impressive Results from an Independent SARS-CoV-2 Antibody Detection Study Conducted in Spain

JERSEY, Channel Islands, July 20, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported that an independent study conducted in Madrid, Spain has confirmed the high perform

QTNT
News
Quotient Limited to Report First Quarter 2021 Financial Results and Host Conference Call

JERSEY, Channel Islands, July 17, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2020 will be released before market open on Monday, August 3, 2020.

View all
Who we are
The future made possible.
Building on over 30 years of experience in transfusion diagnostics, we deliver game changing diagnostic solutions, empowering our customers to realize their full potential and improve their business.
Learn more
Investors
3:59 PM EDT • Aug 5, 2020
QTNT
7.2USD
2.86%
Quotient Limited to Publish Quarterly Investor Presentation
Read More
Quotient Limited Reports First Quarter Fiscal 2021 Results and Business Update
Read More
Quotient Announces Appointment of Two New Board Members
Read More
Read all press releases
Careers
Careers
Help us achieve our mission to transform transfusion diagnostics and beyond.
Joining Quotient is an opportunity to become part of a team that will shape the future of transfusion diagnostics.
Learn more

Available positions

Job title
Department
Location
Manufacturing Technician (6 months)
Production
Eysins, Switzerland
Quality Assurance Engineer
Quality Assurance
Edinburgh, United Kingdom
Instrument Development & Validation Engineer
Instrument
Eysins, Switzerland
View all jobs
Reagents
Alba by Quotient. Experience. Expertise. Value.
These are just some of the qualities that set us apart from the competition. You can have peace of mind using our products, which have been time-tested for more than 30 years.
Learn more

Latest social posts